Dissolution Rate Enhancement, Design and Development of Buccal Drug Delivery of Darifenacin Hydroxypropyl β-Cyclodextrin Inclusion Complexes

Table 6

Evaluation of HPMC K15 patches.

Formulation code	Thickness (mm)	Weight uniformity (mg)	Surface pH	Content uniformity (%)	In vitro drug release (%) (10 hrs)	Swelling index (% weight increase after 3 hrs)
Pb1	0.67±0.07	60.35±0.46	5.93±0.07	94.18±1.81	82.45±1.68	25.4±0.61
Pb2	0.71±0.05	65.33±0.97	5.97±0.056	96.87±2.13	83.26±2.01	27.13±1.03
Pb3	0.74±0.08	67.11±0.73	6.78±0.055	101.37±3.14	84.36±2.44	30.23±1.31
Pb4	0.79±0.07	71.02±1.24	5.99±0.047	93.67±2.14	91.54±2.15	33.42±1.18
Pb5	0.82±0.05	73.57±1.39	6.08±0.074	97.22±1.87	71.44±2.37	37.22±2.54